The mechanism of LZ-8-mediated immune response in the mouse model of Parkinson's disease
Parkinson's disease (PD) is associated with microscopic changes in the brain, particularly substantia nigra (SN). Ganoderma lucidum immunoregulatory protein (rLZ-8) is might confer protective effects against PD. We developed a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced murine m...
Gespeichert in:
Veröffentlicht in: | Journal of neuroimmunology 2023-10, Vol.383, p.578144-578144, Article 578144 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Parkinson's disease (PD) is associated with microscopic changes in the brain, particularly substantia nigra (SN). Ganoderma lucidum immunoregulatory protein (rLZ-8) is might confer protective effects against PD.
We developed a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced murine model of PD and determined the effects of rLZ-8 on molecular and cellular components of SN and whole brain tissue.
The levels of SOD, GSH-Px, p-JAK2 and p-STAT3 in the brain tissue and SN were downregulated, while IL-6, IL-1β, and TNF-α and MDA were upregulated. These effects were significantly reversed upon treatment rLZ-8.
In summary, oxidative stress and inflammatory response in PD can be alleviated using rLZ-8.
•The immunogenicity of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) on mice with Parkinson's disease (PD) was investigated.•Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in PD-like phenotype and decreased the level of SOD, GSH-Px, p-JAK2 and p-STAT3 in the brain.•The grid residence, rod turning, and rod climbing times in PD group were significantly prolonged, and the MDA , IL-6, IL-1β, and TNF-α levels in brain were greatly increased.•Treatment with rLZ-8 was found to reverse the parkinsonism-related effects of MPTP in mice. |
---|---|
ISSN: | 0165-5728 1872-8421 |
DOI: | 10.1016/j.jneuroim.2023.578144 |